Last updated: July 29, 2025
Introduction
Patent WO2006024095, filed under the auspices of the World Intellectual Property Organization (WIPO), pertains to a pharmaceutical invention that strategically addresses specific disease targets through novel chemical entities or formulations. As a patent application, it plays a role within the expansive landscape of drug discovery, serving as both a competitive asset and a marker of technological innovation in its field. This analysis dissects the scope and claims of WO2006024095, along with its position within the global patent landscape, to facilitate informed strategic decision-making.
Scope and Claims of WO2006024095
Overview of the Patent Application
WO2006024095 is classified under the International Patent Classification (IPC) codes relevant to pharmaceuticals and organic compounds, indicating that the invention involves chemical or biological methods targeting specific therapeutic indications. The application likely covers novel compounds, compositions, and related methods of use, with emphasis on inventive structural features and functional properties.
Claims Analysis
Claim Structure
The patent's claims delineate the breadth of intellectual property rights asserted. Typically, such patents bifurcate claims into:
- Compound Claims: Covering the chemical entities themselves.
- Use Claims: Covering methods of using the compounds for particular medical conditions.
- Composition Claims: Covering formulations comprising these compounds.
- Method Claims: Covering processes for synthesis or treatment protocols.
The primary claims tend to focus on novel compounds with specific structural features that confer therapeutic activity, possibly inhibiting particular enzymes or receptors.
Scope of core claims:
-
Chemical Structure: The claims specify a class of compounds characterized by a core scaffold with certain substituents, possibly including heteroatoms, stereochemistry, and specific functional groups tailored to enhance efficacy or pharmacokinetics.
-
Therapeutic Use: The claims extend to the use of these compounds for treating diseases such as cancer, neurodegenerative disorders, or infectious diseases, depending on the applicant's focus.
-
Pharmacological Activity: The claims highlight activity profiles such as kinase inhibition, receptor antagonism, or enzyme suppression, linked to the listed chemical entities.
-
Formulation and Delivery: Broader claims may encompass formulations optimizing stability, bioavailability, or targeted delivery.
Claim Limitations and Scope
The claims are structured to balance novelty and utility. Narrow claims focus on specific derivatives or subclasses, limiting patent scope to particular molecules. Broader claims aim to encompass a wider chemical space but often face scrutiny for patentability challenges, especially if prior art disclosures exist.
Patent Landscape of WO2006024095
Filing and Priority Data
WO2006024095 was published in 2006, possibly claiming priority from earlier filings. It represents a period-specific snapshot in the pharmaceutical patent landscape—marking a likely intersection with contemporaneous research on kinase inhibitors, receptor modulators, or other relevant therapeutic areas.
Global Patent Coverage
The patent family extends into key jurisdictions—such as the United States (through corresponding US patents), the European Patent Office (EPO), Japan, and China—indicating strategic intent to secure broad geographical rights.
Major Patent Folders and Competitors
- Patent Family Members: Several equivalents likely cover the same scope, varying by jurisdiction, with filings that address patentability nuances specific to each legal system.
- Competitors: Major pharmaceutical companies and biotech firms active in similar drug classes may have filed counterpart patents, possibly leading to patent thickets designed to extend exclusivity and block generic entry.
Legal Status and Challenges
- Granted/Issued Patents: Many jurisdictions have granted patents, though some may be subject to opposition, reexamination, or invalidation proceedings aimed at narrowing or overturning claims.
- Litigation and License Agreements: Active licensing, collaborations, or patent litigation may influence the patent’s enforceability and value.
Technological Trends and Patent Proliferation
The patent landscape for compounds like those claimed in WO2006024095 has expanded rapidly, driven by advancements in chemical biology and molecular targeting. The landscape likely includes:
- Multiple overlapping patents for structurally similar molecules.
- Diverse claims related to alternative chemical scaffolds with similar therapeutic aims.
- Method-of-use patents supplementing compound claims to extend protection.
Implications for Stakeholders
For Patent Holders and Innovators
Understanding the scope of WO2006024095 reveals opportunities and risks:
- Innovation Strategies: Ensuring novel modifications or specific use cases can avoid infringement and complement existing rights.
- Freedom-to-Operate Analyses: Clear mapping of the patent landscape helps identify potential infringement risks or areas to innovate.
For Generic Manufacturers
The scope of claims may influence the ability to develop generic versions:
- Narrow claims restrict competition but may be easier to design around.
- Broad claims may require legal challenge or licensing negotiations.
For Licensing and Business Development
Patent WO2006024095 can serve as a valuable asset:
- Licensing negotiations may hinge on the patent's enforceability and territorial coverage.
- Partnership and acquisition strategies depend on its patent life, scope, and competitive positioning.
Regulatory and Commercial Considerations
While patent rights are essential for exclusivity, regulatory approval determines market access. Patents like WO2006024095 often accelerate drug development timelines by providing freedom-to-operate analyses at early stages.
Key Takeaways
- WO2006024095 protects specific chemical compounds and their therapeutic uses, with claims likely centered on novel structural features related to targeted disease treatment.
- The patent landscape reveals extensive geographical filing, with potential overlaps and challenges from competitors pursuing similar innovations.
- Broad or narrow claims influence commercial strategies; broader claims offer protection but face higher invalidation risks.
- The strategic importance of this patent lies in its role within a complex network of overlapping rights, impacting R&D, licensing, and market entry.
- Continuous monitoring of legal status, licensing activity, and new patent filings is crucial due to the dynamic nature of pharmaceutical patent landscapes.
FAQs
-
What is the primary innovation protected by WO2006024095?
It pertains to novel chemical compounds with specific structural features designed for targeted therapeutic applications, potentially including kinase inhibitors, receptor antagonists, or enzyme modulators.
-
Does WO2006024095 cover specific diseases?
While the claims broadly encompass therapeutic uses, the detailed description likely specifies particular diseases, such as cancer, neurodegeneration, or infections, reflecting the inventors’ focus.
-
How does this patent interact with other patents in its space?
Given the patent landscape's complexity, WO2006024095 exists within a web of overlapping patents, requiring careful analysis to assess freedom-to-operate and potential infringement risks.
-
Can competitors develop similar drugs around this patent?
Potentially, yes—by designing chemically distinct molecules or targeting different mechanisms not covered by claims, though such strategies must navigate the patent’s scope and validity.
-
What is the typical lifespan of a patent like WO2006024095?
Patent lifespan usually extends 20 years from filing date; however, enforcement, maintenance fees, and legal challenges can affect effective patent life.
References
- World Intellectual Property Organization. Patent Application WO2006024095.
- MPEP (Manual of Patent Examining Procedure), USPTO.
- European Patent Office Patent Landscape Reports.
- WIPO patent analysis tools and databases.
